Expertise in
1
conditions

Dr. Ramey D. Littell

Permanente Medical Group Inc
San Francisco, CA
Expertise in
1
conditions
Specialties:Obstetrics and Gynecology
Expertise in
1
conditions
OverviewInsuranceLocationsClinical Research

Overview

Ramey Littell is an Obstetrics and Gynecologist in San Francisco, California. Dr. Littell is highly rated in 1 condition, according to our data. His top areas of expertise are Ovarian Cancer, Vaginal Cancer, Endometrial Cancer, Oophorectomy, and Hysterectomy.

His clinical research consists of co-authoring 28 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Florida College Of Medicine
Specialties
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in CA
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

PERMANENTE MEDICAL GROUP INC
2238 Geary Blvd, San Francisco, CA 94115
415-833-2200

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: January 07, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2024
Intervention Type: Procedure, Drug, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2024
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 08, 2023
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2023
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer
Enrollment Status: Completed
Publish Date: March 08, 2022
Intervention Type: Drug
Study Drug: Bupropion Hydrochloride
Study Phase: Phase 2
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

28 Total Publications

NRG-CC004 ancillary data study-exploring the effect of bupropion on sexual desire in female cancer survivors with and without vulvovaginal symptoms.
NRG-CC004 ancillary data study-exploring the effect of bupropion on sexual desire in female cancer survivors with and without vulvovaginal symptoms.
Journal: The journal of sexual medicine
Published: November 22, 2023
Similar Doctors
Expertise in
6
conditions
Dr. Heather G. Huddleston
Obstetrics and Gynecology | Endocrinology
Expertise in
6
conditions
Dr. Heather G. Huddleston
Obstetrics and Gynecology | Endocrinology

University Of California San Francisco

400 Parnassus Ave, Mcb300, 
San Francisco, CA 
 (1.6 mi)
415-476-1000
Languages Spoken:
English
See accepted insurances

Heather Huddleston is an Obstetrics and Gynecologist and an Endocrinologist in San Francisco, California. Dr. Huddleston is highly rated in 6 conditions, according to our data. Her top areas of expertise are Ovarian Cysts, Polycystic Ovary Syndrome, Infertility, and Asherman Syndrome.

Expertise in
25
conditions
Dr. John K. Chan
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
25
conditions
Dr. John K. Chan
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Sutter Bay Medical Foundation

3838 California St, Rm 410, 
San Francisco, CA 
 (0.9 mi)
415-751-1847
Languages Spoken:
English
Offers Telehealth

John Chan is a Gynecologic Oncologist and an Oncologist in San Francisco, California. Dr. Chan is highly rated in 25 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Hysterectomy, and Oophorectomy.

Expertise in
15
conditions
Dr. Jocelyn S. Chapman
Obstetrics and Gynecology
Expertise in
15
conditions
Dr. Jocelyn S. Chapman
Obstetrics and Gynecology

University Of California San Francisco

2330 Post St, 
San Francisco, CA 
 (0.1 mi)
415-476-4029
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jocelyn Chapman is an Obstetrics and Gynecologist in San Francisco, California. Dr. Chapman is highly rated in 15 conditions, according to our data. Her top areas of expertise are Ovarian Cancer, Testicular Yolk Sac Tumor, Cervical Cancer, Hysterectomy, and Oophorectomy.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile